PTH 1-84 (parathyroid hormone) / Studies

Natural peptide · 84 amino acids · 9,425 Da

PTH 1-84 (parathyroid hormone) studies and research data

PepBank has 56 parathyroid hormone studies with results. All of them gave parathyroid hormone, with 418 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 418 results and 279 papers. Newer studies from Europe PMC

Results in people

270

65% of 418 results

Results in animals

148

35% of 418 results

Results in lab cells

0% of 418 results

From computer models

0% of 418 results

The molecule

PTH 1-84 identity

Identifiers, parent molecule, targets and development stage, from curated data.

This record covers intact human PTH(1-84), including the historical recombinant Natpara/Natpar product. It differs from teriparatide and long-acting PTH prodrugs. Natpar's EU authorisation ended in 2026.

Kind: Natural peptide · 84 residues
Identifiers: ChEMBLCHEMBL2108078 (opens in a new tab)UNIIN19A0T0E5J (opens in a new tab)DrugBankDB05829 (opens in a new tab)CAS9002-64-6
Parent: Fragment of Human preproparathyroid hormone · residues 32-115The 84-residue sequence is the mature hormone at UniProt P01270 residues 32-115.
Development: Approved in the US (Natpara, 2015)Intact recombinant human PTH(1-84) reached approval. Natpara manufacturing ended in December 2024, and its special-use program ended in December 2025. EU Natpar and Preotact authorisations are withdrawn. This historical phase does not establish current availability. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Parathyroid hormone 1 receptorPTH1RQ03431 (opens in a new tab)	Agonist	UniProt P01270 function and Q03431 receptor annotationSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

84 amino acids

H-

SVSEIQLMHN

LGKHLNSMER

VEWLRKKLQD

VHNFVALGAP

LAPRDAGSQR

PRKKEDNVLV

ESHEKSLGEA

DKADVNVLTK

AKSQ

-OH

Parent: Human preproparathyroid hormone

No sequence is listed for the parent, so no alignment is shown.The 84-residue sequence is the mature hormone at UniProt P01270 residues 32-115.

Properties

From identity sources

Molecular weight: 9,425 g/mol

GSRS UNII N19A0T0E5J(opens in a new tab)retrieved 2026-10-27
Curated Natpara US label(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Average mass: 9,424.73 Da; Sum of ExPASy residue masses + water · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 9,418.9646 Da; Sum of ExPASy residue masses + water · ExPASy FindMod
Isoelectric point (pI): 9.91; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 2.39; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.740; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 5,500 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 40.57; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 87.0; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 2.42 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.635; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 9.91Bjellqvist (ExPASy) 9.10IPC peptide 9.77IPC protein 8.46

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 9.91 · Net charge at pH 7.4: 2.39

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.

Show as table

pH	Net charge
0	19.00
1	18.99
2	18.86
3	17.72
4	12.39
5	7.07
6	5.17
7	2.95
8	1.91
9	1.16
10	−0.21
11	−4.67
12	−8.67
13	−11.74
14	−12.84

Composition

Hydrophobic33% (28)A I L M V
Aromatic2% (2)F W
Positive21% (18)H K R
Negative14% (12)D E
Polar20% (17)N Q S T
Special8% (7)G P

84 residues. Each residue counts in one class; F and W count as aromatic.

A Ala7 · 8%

I Ile1 · 1%

L Leu10 · 12%

M Met2 · 2%

V Val8 · 10%

F Phe1 · 1%

W Trp1 · 1%

Y Tyr0 · 0%

H His4 · 5%

K Lys9 · 11%

R Arg5 · 6%

D Asp5 · 6%

E Glu7 · 8%

N Asn5 · 6%

Q Gln4 · 5%

S Ser7 · 8%

T Thr1 · 1%

C Cys0 · 0%

G Gly4 · 5%

P Pro3 · 4%

3D structure

PredictedAlphaFold DB · P01270

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.023
μH, best 11-residue window: 0.635
Arrow direction: 180°
Residues: 1–54 of 84 · 3 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	S	0°	-0.18
2	V	100°	1.08
3	S	200°	-0.18
4	E	300°	-0.74
5	I	40°	1.38
6	Q	140°	-0.85
7	L	240°	1.06
8	M	340°	0.64
9	H	80°	-0.40
10	N	180°	-0.78
11	L	280°	1.06
12	G	20°	0.48
13	K	120°	-1.50
14	H	220°	-0.40
15	L	320°	1.06
16	N	60°	-0.78
17	S	160°	-0.18
18	M	260°	0.64
19	E	0°	-0.74
20	R	100°	-2.53
21	V	200°	1.08
22	E	300°	-0.74
23	W	40°	0.81
24	L	140°	1.06
25	R	240°	-2.53
26	K	340°	-1.50
27	K	80°	-1.50
28	L	180°	1.06
29	Q	280°	-0.85
30	D	20°	-0.90
31	V	120°	1.08
32	H	220°	-0.40
33	N	320°	-0.78
34	F	60°	1.19
35	V	160°	1.08
36	A	260°	0.62
37	L	0°	1.06
38	G	100°	0.48
39	A	200°	0.62
40	P	300°	0.12
41	L	40°	1.06
42	A	140°	0.62
43	P	240°	0.12
44	R	340°	-2.53
45	D	80°	-0.90
46	A	180°	0.62
47	G	280°	0.48
48	S	20°	-0.18
49	Q	120°	-0.85
50	R	220°	-2.53
51	P	320°	0.12
52	R	60°	-2.53
53	K	160°	-1.50
54	K	260°	-1.50

Results by area

PTH 1-84 results by year and outcome

Counts are exact and come from studies that gave the peptide.

Parathyroid hormone has 279 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

Studies by year

56 of 279 studies have results (20%), published 1993 to 2026. Top row: every study. Bottom row: studies with results about PTH 1-84 (parathyroid hormone), by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies279 in all, 1975 to 2026

Studies with results56 in all, 1993 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

PTH 1-84 studies on bones and joints

292 results · people 154 · animals 138 · lab 0

Top 5 of 292 results

In hypoparathyroidism, PTH increased undercarboxylated osteocalcin more than placebo.The Journal of clinical endocrinology and metabolism, 2015
In healthy postmenopausal volunteers, rhPTH(1-84) increased serum ionized calcium dose dependently.Clinical pharmacology and therapeutics, 1997
In postmenopausal women, PTH increased spine bone density by 2.1% versus placebo at 12 months.The Journal of clinical endocrinology and metabolism, 2008
In healthy postmenopausal volunteers, rhPTH(1-84) increased serum total calcium dose dependently.Clinical pharmacology and therapeutics, 1997
In osteoporotic women, PTH reduced vertebral fracture risk versus placebo when noncompleters were assumed fracture-free.Annals of internal medicine, 2007

PTH 1-84 studies on salt, water and minerals

38 results · people 36 · animals 2 · lab 0

Top 5 of 38 results

In adults with hypoparathyroidism, more rhPTH(1-84) recipients than placebo recipients reduced both supplements by at least 50% while maintaining blood calcium.The lancet. Diabetes & endocrinology, 2013
In osteoporotic women, PTH(1-84) and PTH(1-34) did not differ in ionized calcium changes.Calcified tissue international, 2009
In adults with chronic hypoparathyroidism, twice-daily versus once-daily rhPTH(1-84) showed no pharmacodynamic differences considered clinically meaningful.JBMR plus, 2023
In osteoporotic women, ionized calcium after PTH(1-84) was virtually identical to baseline at 24 hours.Calcified tissue international, 2009
In hypoparathyroidism, PTH reduced blood phosphate versus placebo.Endocrine, 2017

PTH 1-84 studies on side effects

33 results · people 29 · animals 4 · lab 0

Top 5 of 33 results

In osteoporotic women, high blood calcium occurred more often with PTH than with placebo.Annals of internal medicine, 2007
In adults with chronic hypoparathyroidism receiving rhPTH(1-84), no new safety findings were observed.JBMR plus, 2023
In osteoporotic women, nausea occurred more often with PTH than with placebo.Annals of internal medicine, 2007
In osteoporotic women, hypercalciuria occurred more often with PTH than with placebo.Annals of internal medicine, 2007
In women receiving PTH, bone biopsies showed no adverse effects on bone.Current medical research and opinion, 2010

PTH 1-84 studies on daily life and fitness

19 results · people 19 · animals 0 · lab 0

Top 5 of 19 results

In chronic hypoparathyroidism, PTH did not significantly improve SF-36 scores versus placebo at week 24.The Journal of clinical endocrinology and metabolism, 2018
In elderly women with osteoporosis and pelvic fractures, PTH improved mobility test performance versus control.The Journal of bone and joint surgery. American volume, 2011
In symptomatic chronic hypoparathyroidism, rhPTH(1-84) reduced symptom scores more than placebo at week 26.European journal of endocrinology, 2025
In hypoparathyroidism, PTH did not improve quality of life versus placebo.Osteoporosis international, 2014
In hypoparathyroidism, PTH did not improve muscle function versus placebo.Osteoporosis international, 2014

PTH 1-84 studies on kidneys and bladder

10 results · people 9 · animals 1 · lab 0

Top 3 of 10 results

In adults with chronic hypoparathyroidism, twice-daily rhPTH(1-84) reduced urinary calcium numerically more than once-daily dosing.JBMR plus, 2023
In adults with chronic hypoparathyroidism receiving extended rhPTH(1-84), mean urinary calcium excretion was within the reference range at treatment end.Endocrine practice, 2024
In people with hypoparathyroidism, urinary calcium was mostly unchanged after 24 months of PTH treatment.Osteoporosis international, 2010

PTH 1-84 studies on blood levels and clearance

9 results · people 8 · animals 1 · lab 0

Top 3 of 9 results

In adults with chronic hypoparathyroidism, rhPTH(1-84) exposure generally increased with dose, but not proportionally.JBMR plus, 2023
In hypoparathyroidism, PTH blood levels peaked 15 minutes after injection.Journal of bone and mineral research, 2013
In healthy postmenopausal volunteers, rhPTH(1-84) produced two serum concentration peaks after administration.Clinical pharmacology and therapeutics, 1997

PTH 1-84 studies on hormones

6 results · people 6 · animals 0 · lab 0

Top 5 of 6 results

In patients with hypoparathyroidism, PTH reduced calcium supplement doses by 75% versus placebo.Journal of bone and mineral research, 2011
In adults with chronic hypoparathyroidism receiving extended rhPTH(1-84), mean calcium supplement doses were maintained throughout the study.Endocrine practice, 2024
In people with hypoparathyroidism, calcium supplement requirements fell during PTH treatment.Osteoporosis international, 2010
In adults with chronic hypoparathyroidism receiving extended rhPTH(1-84), mean active vitamin D doses were maintained throughout the study.Endocrine practice, 2024
In patients with hypoparathyroidism, PTH reduced active vitamin D doses by 73% versus placebo.Journal of bone and mineral research, 2011

PTH 1-84 studies on blood sugar

4 results · people 4 · animals 0 · lab 0

Top 3 of 4 results

In osteoporotic women, PTH decreased blood glucose versus calcium and colecalcipherol alone.Bone, 2015
In osteoporotic women, PTH did not affect insulin secretion, insulin resistance, or pancreatic beta-cell function versus calcium and colecalcipherol alone.Bone, 2015
In osteoporotic women, PTH did not influence adipokine production versus calcium and colecalcipherol alone.Bone, 2015

PTH 1-84 studies on weight and appetite

4 results · people 2 · animals 2 · lab 0

4 results

In hypoparathyroidism, PTH reduced body weight compared with placebo.The Journal of clinical endocrinology and metabolism, 2015
In osteoporotic women, PTH did not influence fat distribution versus calcium and colecalcipherol alone.Bone, 2015
In rats, human PTH(1-84) treatment produced no observed change in body weight.Journal of bone and mineral research, 1993
In rats, human PTH(1-84) did not change body weight gain.Calcified tissue international, 1993

PTH 1-84 studies on heart and blood vessels

1 result · people 1 · animals 0 · lab 0

1 result

In the hypoparathyroidism PTH trial, glucose, adiponectin, leptin, insulin resistance, total body fat mass, and trunk fat did not change significantly.The Journal of clinical endocrinology and metabolism, 2015

PTH 1-84 studies on pain

1 result · people 1 · animals 0 · lab 0

1 result

In elderly women with osteoporosis and pelvic fractures, PTH improved pain scores versus control.The Journal of bone and joint surgery. American volume, 2011

PTH 1-84 studies on receptors and cell signals

1 result · people 1 · animals 0 · lab 0

1 result

In healthy postmenopausal volunteers, rhPTH(1-84) increased urinary cyclic adenosine monophosphate.Clinical pharmacology and therapeutics, 1997

Trials and papers

PTH 1-84 trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

31 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (25 of 31)

25 of 31 trials

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

199520002005201020152020

Ph 2
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
NCT00172107
18 May 1995 to 24 Mar 1997
Ph 3
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
NCT00172081
27 Apr 2000 to 7 Nov 2003
Ph 3
OLES
NCT00172133
16 Oct 2001 to 13 Apr 2005
Ph 2/3
Bone Properties in Hypoparathyroidism: Effects of PTH
NCT00473265
May 2004 to Jun 2014
Ph 3
TRES
NCT00172120
10 Jan 2005 to 27 Oct 2006
Ph 3
PEAK
NCT00365456
Jul 2006 to Aug 2011
Ph 4
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
NCT00479037
Apr 2007 to Jul 2009
Ph 4
STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)
NCT00583518
Nov 2007 to Feb 2012
Ph 4
The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)
NCT00713258
Apr 2008 to Sept 2010
Terminated
Terminated
Ph 2/3
PICS
NCT00683163
May 2008 to Apr 2011

Browse all 31 matching trials in the list below

25 trials · 21 completed · 3 stopped early · 15 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT03324880

A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)

Shiren = 9324 Jan 2018 to 19 May 2022

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 9 Jun 2023

CompletedPhase 4Results postedNCT02910466

A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism

Shiren = 3927 Oct 2016 to 20 Dec 2019

Chronic Hypoparathyroidism · Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 28 Jul 2021

CompletedPhase 4Results postedNCT00479037

Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)

Nycomedn = 82Apr 2007 to Jul 2009

Osteoporosis

Trial page ClinicalTrials.govUpdated 8 May 2012

TerminatedPhase 4Results postedNCT00713258

The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)

Nycomedn = 75Apr 2008 to Sept 2010

Back Pain

Trial page ClinicalTrials.govUpdated 8 May 2012

CompletedPhase 4NCT00583518

STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)

Nycomedn = 129Nov 2007 to Feb 2012

Postmenopausal Women With Primary Osteoporosis

Trial page ClinicalTrials.govUpdated 7 May 2012

CompletedPhase 3Results postedNCT01199614

HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism

Columbia Universityn = 62Dec 2009 to 26 Jun 2017

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 5 Jul 2024

WithdrawnPhase 3NCT03878953

A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism

Shiren = 0est. 31 Aug 2022 to est. 31 May 2023

Chronic Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 10 Oct 2022

TerminatedPhase 3Results postedNCT03364738

Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism

Shiren = 2226 Sept 2018 to 14 Apr 2020

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 7 Oct 2022

CompletedPhase 3Results postedNCT01268098

Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)

Shiren = 429 Feb 2011 to 11 Nov 2011

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 11 Jun 2021

CompletedPhase 3Results postedNCT01455181

A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary

Shiren = 2419 Aug 2011 to 26 Apr 2012

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 11 Jun 2021

CompletedPhase 3Results postedNCT00732615

Use of NPSP558 in the Treatment of Hypoparathyroidism

Shiren = 12418 Dec 2008 to 28 Sept 2011

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 3 Jun 2021

CompletedPhase 3Results postedNCT01297309

A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Shiren = 516 Apr 2011 to 8 Jun 2018

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 25 May 2021

CompletedPhase 3NCT00172120

Open Label Extension

Shiren = 9110 Jan 2005 to 27 Oct 2006

Osteoporosis

Trial page ClinicalTrials.govUpdated 17 May 2021

CompletedPhase 3NCT00172133

Open Label Extension Study of PREOS

Shiren = 1,68316 Oct 2001 to 13 Apr 2005

Osteoporosis

Trial page ClinicalTrials.govUpdated 17 May 2021

CompletedPhase 3NCT00172081

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

Shiren = 2,53227 Apr 2000 to 7 Nov 2003

Osteoporosis

Trial page ClinicalTrials.govUpdated 14 May 2021

Status unknownPhase 3NCT00856401

ADD-ON Study to Existing Hypoparathyroidism Studies

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)n = 62Sept 2010 to est. 30 Jun 2021

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 28 Feb 2018

CompletedPhase 2/3Results postedNCT00473265

Bone Properties in Hypoparathyroidism: Effects of PTH

John P. Bilezikiann = 68May 2004 to Jun 2014

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 16 Jul 2015

CompletedPhase 3NCT01466829

Treatment With PTH After Sternotomy in Cardiac Surgery Patients

University of Aarhusn = 20Oct 2012 to Mar 2014

Disruption or Dehiscence of Closure of Sternum or Sternotomy

Trial page ClinicalTrials.govUpdated 2 Jun 2014

CompletedPhase 2/3Results postedNCT00683163

PTH & Ibandronate Combination Study (PICS)

University of California, San Franciscon = 44May 2008 to Apr 2011

Osteoporosis

Trial page ClinicalTrials.govUpdated 5 Nov 2013

CompletedPhase 3Results postedNCT00365456

Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)

Takedan = 407Jul 2006 to Aug 2011

Osteoporosis

Trial page ClinicalTrials.govUpdated 20 Aug 2012

CompletedPhase 2NCT00172107

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

Shiren = 21718 May 1995 to 24 Mar 1997

Osteoporosis

Trial page ClinicalTrials.govUpdated 17 May 2021

CompletedPhase 2NCT03516773

Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism

Entera Bio Ltd.n = 2017 Jun 2018 to 24 Feb 2019

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 26 Mar 2019

CompletedPhase 2NCT00730210

Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life

University of Aarhusn = 62Jun 2008 to Aug 2010

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 24 Oct 2012

CompletedPhase 1Results postedNCT05137730

A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

Takedan = 9629 Nov 2021 to 15 Apr 2022

Healthy Volunteers

Trial page ClinicalTrials.govUpdated 15 Dec 2023

CompletedPhase 1Results postedNCT03150108

Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects

Shiren = 2416 May 2017 to 26 Jun 2017

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 8 Jun 2021

5 more mention it but do not test it. They are not trials of PTH 1-84 (parathyroid hormone): they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

279 studies match. Retracted studies are left out.

Showing 23 of 279 studiesquery qry_cb92ed9bd4f769991a755d88

Studies with results

56 studies in all, 12 on this page

Randomized controlled trial · 2003

4 results

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Black et al. 2003The New England journal of medicinen = 179cited by 788

PMID 14500804DOI 10.1056/nejmoa031975PUB-14500804

Full text at the publisher4 results where PTH 1-84 (parathyroid hormone) was given

Publisher page See results (4)

Randomized controlled trial · 2007

9 results

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.

Greenspan et al. 2007Annals of internal medicinecited by 298

PMID 17339618DOI 10.7326/0003-4819-146-5-200703060-00005PUB-17339618

Full text at the publisher9 results where PTH 1-84 (parathyroid hormone) was given

Publisher page See results (9)

Randomized controlled trial · 2011

4 results

Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women.

Peichl et al. 2011The Journal of bone and joint surgery. American volumen = 65cited by 237

PMID 21915572DOI 10.2106/jbjs.j.01379PUB-21915572

Full text at the publisher4 results where PTH 1-84 (parathyroid hormone) was given

Publisher page See results (4)

Animal study (in vivo) · rat · 2000

2 results

A novel mechanism for skeletal resistance in uremia.

Slatopolsky et al. 2000Kidney internationalcited by 222

PMID 10916099DOI 10.1046/j.1523-1755.2000.00222.xPUB-10916099

Full text at the publisher2 results where PTH 1-84 (parathyroid hormone) was given

Publisher page See results (2)

Non-randomized trial · 2000

4 results

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.

Rittmaster et al. 2000The Journal of clinical endocrinology and metabolismcited by 196

PMID 10852440DOI 10.1210/jcem.85.6.6614PUB-10852440

Rights unknown4 results where PTH 1-84 (parathyroid hormone) was given

Source link See results (4)

Randomized controlled trial · 2013

Corrected4 results

Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.

Mannstadt et al. 2013The lancet. Diabetes & endocrinologyn = 134cited by 176

PMID 24622413DOI 10.1016/s2213-8587(13)70106-2PUB-24622413

Full text at the publisher4 results where PTH 1-84 (parathyroid hormone) was given

Publisher page Read the notice See results (4)

Non-randomized trial · 2008

2 results

Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans.

Keaveny et al. 2008Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 161

PMID 18684084PMC2686921DOI 10.1359/jbmr.080805PUB-18684084

Rights unknown2 results where PTH 1-84 (parathyroid hormone) was given

Source link See results (2)

Non-randomized trial · 2003

11 results

Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis.

Hodsman et al. 2003The Journal of clinical endocrinology and metabolismcited by 138

PMID 14602752DOI 10.1210/jc.2003-030768PUB-14602752

Full text at the publisher11 results where PTH 1-84 (parathyroid hormone) was given

Publisher page See results (11)

Randomized controlled trial · 2011

16 results

The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study.

Sikjaer et al. 2011Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchn = 62cited by 132

PMID 21773992DOI 10.1002/jbmr.470PUB-21773992

Rights unknown16 results where PTH 1-84 (parathyroid hormone) was given

Source link See results (16)

Animal study (in vivo) · rat · 1993

16 results

Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats.

Ejersted et al. 1993Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 99

PMID 8237479DOI 10.1002/jbmr.5650080910PUB-08237479

Full text at the publisher8 results where PTH 1-84 (parathyroid hormone) was given

Publisher page See results (16)

Randomized controlled trial · 2014

7 results

Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial.

Sikjaer et al. 2014Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAn = 62cited by 95

PMID 24687385DOI 10.1007/s00198-014-2677-6PUB-24687385

Full text at the publisher7 results where PTH 1-84 (parathyroid hormone) was given

Publisher page See results (7)

Animal study (in vivo) · rat · 2006

13 results

Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats.

Jolette et al. 2006Toxicologic pathologycited by 91

PMID 17178693DOI 10.1080/01926230601072301PUB-17178693

Rights unknown13 results where PTH 1-84 (parathyroid hormone) was given

Source link See results (13)

More studies

212 studies in all, 11 on this page

PubMed tag: Randomized Controlled Trial, Clinical Trial · 1995

Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial.

Ooms et al. 1995The Journal of clinical endocrinology and metabolismcited by 257

PMID 7714065DOI 10.1210/jcem.80.4.7714065PUB-07714065

Full text at the publisher

Publisher page

PubMed tag: Randomized Controlled Trial, Clinical Trial · 1988

The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects.

Lips et al. 1988The Journal of clinical endocrinology and metabolismcited by 246

PMID 3417845DOI 10.1210/jcem-67-4-644PUB-03417845

Full text at the publisher

Publisher page

PubMed tag: Network Meta-Analysis · 2019

Corrected

Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.

Barrionuevo et al. 2019The Journal of clinical endocrinology and metabolismcited by 232

PMID 30907957DOI 10.1210/jc.2019-00192PUB-30907957

Full text at the publisher

Publisher page Read the notice

PubMed tag: none · 1992

The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition.

Binnerts et al. 1992Clinical endocrinologycited by 172

PMID 1424196DOI 10.1111/j.1365-2265.1992.tb02287.xPUB-01424196

Full text at the publisher

Publisher page

PubMed tag: none · 1996

Parathyroid hormone-related peptide (PTHrP) regulates fetal-placental calcium transport through a receptor distinct from the PTH/PTHrP receptor.

Kovacs et al. 1996Proceedings of the National Academy of Sciences of the United States of Americacited by 155

PMID 8986793PMC26386DOI 10.1073/pnas.93.26.15233PUB-08986793

Rights unknown

Source link

PubMed tag: none · 2001

Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients.

Monier-Faugere et al. 2001Kidney internationalcited by 142

PMID 11576360DOI 10.1046/j.1523-1755.2001.00949.xPUB-11576360

Full text at the publisher

Publisher page

PubMed tag: none · 1994

Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD.

Salusky et al. 1994Kidney internationalcited by 117

PMID 8127016DOI 10.1038/ki.1994.31PUB-08127016

Full text at the publisher

Publisher page

PubMed tag: Randomized Controlled Trial, Clinical Trial · 1993

Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.

Nussbaum et al. 1993The American journal of medicinecited by 116

PMID 8368227DOI 10.1016/0002-9343(93)90282-tPUB-08368227

Full text at the publisher

Publisher page

PubMed tag: Randomized Controlled Trial, Clinical Trial · 1998

Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly.

Chel et al. 1998Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 113

PMID 9718191DOI 10.1359/jbmr.1998.13.8.1238PUB-09718191

Rights unknown

Source link

PubMed tag: Clinical Trial · 2011

PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism.

Rubin et al. 2011Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 97

PMID 21735476PMC4019384DOI 10.1002/jbmr.452PUB-21735476

Rights unknown

Source link

PubMed tag: Randomized Controlled Trial · 2009

Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study.

Stein et al. 2009Clinical endocrinologycited by 91

PMID 19018785PMC2918432DOI 10.1111/j.1365-2265.2008.03470.xPUB-19018785

Rights unknown

Source link

No result for PTH 1-84 (parathyroid hormone) (2 studies on this page, 11 in all)

These studies name PTH 1-84 (parathyroid hormone) but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Randomized Controlled Trial, Clinical Trial · 2005

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.

Black et al. 2005The New England journal of medicinecited by 404

PMID 16093464DOI 10.1056/nejmoa050336PUB-16093464

Full text at the publisher

Publisher page

PubMed tag: Observational Study · 2013

9 results

Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT.

Hansen et al. 2013Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 112

PMID 23044908DOI 10.1002/jbmr.1784PUB-23044908

Rights unknown9 results

Source link See results (9)

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

PTH 1-84 (parathyroid hormone) studies: 56 papers with results

Page 1 of 2

Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
Mannstadt M · The lancet. Diabetes & endocrinology · 2013
Randomized controlled trial · 4 results
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes.
Brandi ML · European journal of endocrinology · 2025
Randomized controlled trial · 4 results
The Effect of Treatment With PTH on Undercarboxylated Osteocalcin and Energy Metabolism in Hypoparathyroidism.
Harsløf T · The Journal of clinical endocrinology and metabolism · 2015
Randomized controlled trial · 7 results
Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.
Black DM · The Journal of clinical endocrinology and metabolism · 2008
Randomized controlled trial · 8 results
A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism.
Ing SW · JBMR plus · 2023
Randomized controlled trial · 10 results
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
Greenspan SL · Annals of internal medicine · 2007
Randomized controlled trial · 9 results
Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
Fogelman I · Calcified tissue international · 2008
Randomized controlled trial · 12 results
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Black DM · The New England journal of medicine · 2003
Randomized controlled trial · 4 results
Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
Sellmeyer DE · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007
Randomized controlled trial · 5 results
Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
Clarke BL · Endocrine · 2017
Randomized controlled trial · 6 results
Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.
Vokes TJ · The Journal of clinical endocrinology and metabolism · 2018
Randomized controlled trial · 6 results
The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.
Quesada-Gómez JM · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2011
Randomized controlled trial · 5 results
Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women.
Peichl P · The Journal of bone and joint surgery. American volume · 2011
Randomized controlled trial · 4 results
The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study.
Sikjaer T · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2011
Randomized controlled trial · 16 results
Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial.
Sikjaer T · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014
Randomized controlled trial · 7 results
Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study.
Sikjaer T · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012
Randomized controlled trial · 12 results
Transitory Activation and Improved Transition from Erosion to Formation within Intracortical Bone Remodeling in Hypoparathyroid Patients Treated with rhPTH(1-84).
van Dijk Christiansen P · JBMR plus · 2023
Randomized controlled trial · 12 results
Effect of intermittent PTH treatment on plasma glucose in osteoporosis: A randomized trial.
D'Amelio P · Bone · 2015
Randomized controlled trial · 8 results
PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Sikjaer T · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2013
Randomized controlled trial · 11 results
Intratrabecular bone remodeling - a previously overlooked mode of remodeling hyperactivated by parathyroid hormone.
Thomsen LK · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
Randomized controlled trial · 8 results
Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic Hypoparathyroidism.
Rubin MR · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2024
Non-randomized trial · 11 results
AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
Lakatos P · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016
Non-randomized trial · 6 results
Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses.
Bilezikian JP · Clinical therapeutics · 2017
Non-randomized trial · 6 results
Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study).
Schafer AL · The Journal of clinical endocrinology and metabolism · 2011
Non-randomized trial · 1 result
Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study.
Garnero P · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2008
Non-randomized trial · 2 results
Therapy of hypoparathyroidism with intact parathyroid hormone.
Rubin MR · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010
Non-randomized trial · 7 results
Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
Recker RR · Bone · 2009
Non-randomized trial · 19 results
The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1,25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study.
Piemonte S · Calcified tissue international · 2009
Non-randomized trial · 12 results
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
Rittmaster RS · The Journal of clinical endocrinology and metabolism · 2000
Non-randomized trial · 4 results
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans.
Keaveny TM · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2008
Non-randomized trial · 2 results
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis.
Hodsman AB · The Journal of clinical endocrinology and metabolism · 2003
Non-randomized trial · 11 results
Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers.
Schwietert HR · Clinical pharmacology and therapeutics · 1997
Non-randomized trial · 9 results
Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.
Zanchetta JR · Current medical research and opinion · 2010
Non-randomized trial · 9 results
Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.
Black DM · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013
Non-randomized trial · 10 results
Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
Bauer DC · The Journal of clinical endocrinology and metabolism · 2006
Observational study · 5 results
Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis.
Schafer AL · Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry · 2011
Observational study · 6 results
Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats.
Rhee Y · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2004
Animal study (in vivo) · rat · 8 results
A novel mechanism for skeletal resistance in uremia.
Slatopolsky E · Kidney international · 2000
Animal study (in vivo) · rat · 2 results
Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats.
Ejersted C · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 1993
Animal study (in vivo) · rat · 16 results
Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats.
Jolette J · Toxicologic pathology · 2006
Animal study (in vivo) · rat · 13 results
Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum.
Oxlund H · Calcified tissue international · 1993
Animal study (in vivo) · rat · 28 results
Effects of continuous infusion of PTH on experimental tooth movement in rats.
Soma S · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 1999
Animal study (in vivo) · rat · 6 results
Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J · Calcified tissue international · 2006
Animal study (in vivo) · rat · 21 results
Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats.
Jahng JS · Orthopedics · 2000
Animal study (in vivo) · rat · 2 results
Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats.
Kim HW · The Iowa orthopaedic journal · 1999
Animal study (in vivo) · rat · 2 results
Cartilaginous repair of full-thickness articular cartilage defects is induced by the intermittent activation of PTH/PTHrP signaling.
Kudo S · Osteoarthritis and cartilage · 2011
Animal study (in vivo) · japanese white rabbits · 5 results
Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
Mitlak BH · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 1996
Animal study (in vivo) · rat · 6 results
Enhanced osteoblast development after continuous infusion of hPTH(1-84) in the rat.
Watson PH · Bone · 1999
Animal study (in vivo) · rat · 9 results
Inhibition of chondrogenesis by parathyroid hormone in vivo during repair of full-thickness defects of articular cartilage.
Kudo S · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2000
Animal study (in vivo) · rabbit · 4 results
Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1-84.
Miller MA · Bone · 2008
Animal study (in vivo) · rhesus monkeys · 9 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Natpara · 23 Jan 2015	27 Oct 2026	dailymed.nlm.nih.gov (opens in a new tab)
EU	EMA	Natpar Preotact	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Not listed as banned by WADA PTH, Natpara, and Natpar are not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

48 safety results for PTH 1-84 (parathyroid hormone).

Regulatory:

Human evidence· 34

In adults with hypoparathyroidism, six rhPTH(1-84) patients and seven placebo patients discontinued before study end.
Randomized controlled trialn = 134
Discontinuations
6 patients
rhPTH(1-84)
Discontinuations
7 patients
placebo
In adults with hypoparathyroidism, adverse events affected 93% with rhPTH(1-84) versus 100% with placebo, described as similar proportions.
Randomized controlled trialn = 134
Patients with adverse events
84 patients
rhPTH(1-84)
Adverse events
93%
rhPTH(1-84)
Patients with adverse events
44 patients
placebo
1 more measurement in the study.
In adults with hypoparathyroidism, serious adverse events affected 11% with rhPTH(1-84) versus 9% with placebo, described as similar proportions.
Randomized controlled trialn = 134
Serious adverse events
10 patients
rhPTH(1-84)
Serious adverse events
11%
rhPTH(1-84)
Serious adverse events
4 patients
placebo
1 more measurement in the study.
In hypoparathyroidism, hypercalcemic episodes averaged 3.7 ± 2.9 per patient with PTH versus 0.2 ± 0.6 with placebo (P < .001).
Randomized controlled trialn = 58
Hypercalcemic episodes per patient, mean
3.7 episodes
PTH-treated group
Hypercalcemic episodes per patient, SD
2.9 episodes
PTH-treated group
Hypercalcemic episodes per patient, mean
0.2 episodes
placebo group
1 more measurement in the study.
In osteoporotic women, PTH increased the percentage with hypercalciuria by 24% versus placebo (CI 20% to 27%).
Randomized controlled trialn not reported
Increase in participants with hypercalciuria
24%
PTH vs placebo
CI of increase in hypercalciuria
20 to 27%
PTH vs placebo
In osteoporotic women, PTH increased the percentage with hypercalcemia by 23% versus placebo (CI 21% to 26%).
Randomized controlled trialn not reported
Increase in participants with hypercalcemia
23%
PTH vs placebo
CI of increase in hypercalcemia
21 to 26%
PTH vs placebo
In osteoporotic women, PTH increased the percentage with nausea by 14% versus placebo (CI 11% to 16%).
Randomized controlled trialn not reported
Increase in participants with nausea
14%
PTH vs placebo
CI of increase in nausea
11 to 16%
PTH vs placebo
In postmenopausal women, hypercalciuria occurred more frequently with HT plus PTH(1-84) than HT alone.
Randomized controlled trialn not reported

The top 24 of 34 results.

Doses studied · 65

The doses that these studies used. They are not recommendations.

50 μg per day, titrated to 75 μg or 100 μgHuman
Species
human
Route
subcutaneous
Duration
24 weeks
Design
Randomized controlled trial · n = 134
25-100 µg/dayHuman
Species
human
Route
subcutaneous
Duration
Not reported
Design
Randomized controlled trial · n = 93
100 μg/dHuman
Species
human
Route
Not reported
Duration
24 weeks
Design
Randomized controlled trial · n = 58
100 mug daily for 1 month, then weekly for 11 monthsHuman
Species
human
Route
subcutaneous
Duration
12 months
Design
Randomized controlled trial · n = 50
25 μg twice daily, 50 μg twice daily, or 100 μg once dailyHuman
Species
human
Route
subcutaneous
Duration
1 day
Design
Randomized controlled trial · n = 33
100 mug dailyHuman
Species
human
Route
subcutaneous
Duration
18 months
Design
Randomized controlled trial

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
50 μg per day, titrated to 75 μg or 100 μg	Human	human	subcutaneous	24 weeks	Randomized controlled trial · n = 134
25-100 µg/day	Human	human	subcutaneous	Not reported	Randomized controlled trial · n = 93
100 μg/d	Human	human	Not reported	24 weeks	Randomized controlled trial · n = 58
100 mug daily for 1 month, then weekly for 11 months	Human	human	subcutaneous	12 months	Randomized controlled trial · n = 50
25 μg twice daily, 50 μg twice daily, or 100 μg once daily	Human	human	subcutaneous	1 day	Randomized controlled trial · n = 33
100 mug daily	Human	human	subcutaneous	18 months	Randomized controlled trial

6 of 65 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000158
Peptide version: 3
Peptide hash: 711ce8c15b2e59ae…
Data version: 308560

Latest changes

28 Oct 2026UpdatedData version 308545
28 Oct 2026UpdatedData version 304196
27 Oct 2026CreatedData version 256752

For developers

curl -s https://pepbank.io/v1/briefs/parathyroid-hormone

Evidence summary for PTH 1-84 (parathyroid hormone): counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Bone and jointMusculoskeletal	Human: 154 results from 27 studies: 100 increase, 24 decrease, 18 no significant change, 1 mixed, 11 not reported. Strongest design: Randomized controlled trial	Animal: 138 results from 19 studies: 82 increase, 7 decrease, 36 no significant change, 3 mixed, 10 not reported. Strongest design: Animal study (in vivo)	No results	No results	292
Electrolyte balanceEndocrine and hormones	Human: 29 results from 9 studies: 3 increase, 6 decrease, 5 no significant change, 15 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 2 studies: 1 increase, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	31
Adverse eventsWhole body	Human: 26 results from 14 studies: 8 increase, 2 decrease, 16 not reported. Strongest design: Randomized controlled trial	Animal: 4 results from 1 study: 4 not reported. Strongest design: Animal study (in vivo)	No results	No results	30
Quality of lifeWhole body	Human: 12 results from 5 studies: 6 increase, 2 decrease, 2 no significant change, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Kidney functionKidney and urinary	Human: 9 results from 5 studies: 3 increase, 2 decrease, 2 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	10
PharmacokineticsPharmacology	Human: 8 results from 3 studies: 3 increase, 1 decrease, 4 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	9
Calcium MetabolismEndocrine and hormones	Human: 7 results from 1 study: 1 increase, 5 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	7
Exercise and physical functionMusculoskeletal	Human: 7 results from 2 studies: 4 decrease, 1 no significant change, 1 mixed, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	7
Glycemic controlMetabolic and weight	Human: 4 results from 1 study: 1 decrease, 2 no significant change, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	4
Supplement requirementsEndocrine and hormones	Human: 4 results from 2 studies: 4 decrease. Strongest design: Randomized controlled trial	No results	No results	No results	4
Gastrointestinal adverse eventsGastrointestinal	Human: 3 results from 2 studies: 3 increase. Strongest design: Randomized controlled trial	No results	No results	No results	3
Supplement RequirementsEndocrine and hormones	Human: 2 results from 1 study: 2 not reported. Strongest design: Non-randomized trial	No results	No results	No results	2

Outcome group	Human	Animal	Lab	Computer model	Total
Bone and jointMusculoskeletal	Human: 154 results from 27 studies: 100 increase, 24 decrease, 18 no significant change, 1 mixed, 11 not reported. Strongest design: Randomized controlled trial	Animal: 138 results from 19 studies: 82 increase, 7 decrease, 36 no significant change, 3 mixed, 10 not reported. Strongest design: Animal study (in vivo)	No results	No results	292
Electrolyte balanceEndocrine and hormones	Human: 29 results from 9 studies: 3 increase, 6 decrease, 5 no significant change, 15 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 2 studies: 1 increase, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	31
Adverse eventsWhole body	Human: 26 results from 14 studies: 8 increase, 2 decrease, 16 not reported. Strongest design: Randomized controlled trial	Animal: 4 results from 1 study: 4 not reported. Strongest design: Animal study (in vivo)	No results	No results	30
Quality of lifeWhole body	Human: 12 results from 5 studies: 6 increase, 2 decrease, 2 no significant change, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Kidney functionKidney and urinary	Human: 9 results from 5 studies: 3 increase, 2 decrease, 2 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	10
PharmacokineticsPharmacology	Human: 8 results from 3 studies: 3 increase, 1 decrease, 4 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	9
Calcium MetabolismEndocrine and hormones	Human: 7 results from 1 study: 1 increase, 5 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	7
Exercise and physical functionMusculoskeletal	Human: 7 results from 2 studies: 4 decrease, 1 no significant change, 1 mixed, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	7
Glycemic controlMetabolic and weight	Human: 4 results from 1 study: 1 decrease, 2 no significant change, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	4
Supplement requirementsEndocrine and hormones	Human: 4 results from 2 studies: 4 decrease. Strongest design: Randomized controlled trial	No results	No results	No results	4
Gastrointestinal adverse eventsGastrointestinal	Human: 3 results from 2 studies: 3 increase. Strongest design: Randomized controlled trial	No results	No results	No results	3
Supplement RequirementsEndocrine and hormones	Human: 2 results from 1 study: 2 not reported. Strongest design: Non-randomized trial	No results	No results	No results	2